Role of vascular endothelial growth factor in portal hypertensive gastropathy

Digestion

Volumn 61, Issue 2, 2000, Pages 98-106

  Tsugawa, Kouji ^a   Hashizume, Makoto ^a   Migou, Shinichirou ^a   Kishihara, Fumiaki ^a   Kawanaka, Hirofumi ^a   Tomikawa, Morimasa ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Gastric mucosal blood flow; Portal hypertensive gastropathy; Teprenone treatment; Vascular endothelial growth factor

Indexed keywords

HEXOSAMINE; TEPRENONE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; DIGESTIVE TRACT ENDOSCOPY; FEMALE; HUMAN; LIVER CIRRHOSIS; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; STOMACH ANTRUM; STOMACH DISEASE; STOMACH FUNDUS; STOMACH MUCOSA; STOMACH MUCOSA BLOOD FLOW;

EID: 0033997030     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007741     Document Type: Article

References (51)

1. McCormack TT, Sims J, Eyre-Book I, et al: Gastric lesions in portal hypertension: Inflammatory gastritis or congestive gastropathy? Gut 1985;26:1226-1232.
2. Tanoue K, Hashizume M, Wada H, et al: Effects of endoscopic injection selerotherapy on portal hypertensive gastropathy; a prospective study. Gastrointest Endosc 1992;38:582-585.
3. Ohta M, Hashizume M, Higashi H, et al: Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy. Hepatology 1994;20:1432-1436.
4. Panés J, Bordas JM, Piqué JM, et al: Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology 1992;103:1875-1882.
5. Kotzampassi K, Eleftheriadis E, Aletras H, et al: Gastric mucosal blood flow in portal hypertensive patients: A laser Doppler flowmetry study. Hepatogastroenterology 1992;39:39-42.
6. Guslandi M, Sorghi M, Foppa L, et al: Congestive gastropathy versus chronic gastritis: A comparison of some pathophysiological aspects. Digestion 1993;54:160-162.
7. Iwao T, Toyonaga A, Ikegami M, et al: Reduced gastric mucosal blood flow in patients with portal hypertensive gastropathy. Hepatology 1993;18:36-40.
8. Hashizume M, Tanaka K, Inokuchi K: Morphology of gastric microcirculation in cirrhosis. Hepatology 1983;3:1008-1012.
9. Hashizume M, Kitano S, Sugimachi K, et al: Three-dimensional view of the vascular structure of the lower esophagus in clinical portal hypertension. Hepatology 1988;8:1482-1487.
10. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes the accumulation of ascites fluid. Science 1983;219:983-985.
11. Leung DW, Cachianes G, Kuang WJ. et al: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
12. Shibuya M, Yamaguchi S, Yamane A, et al: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-524.
13. Yamane A, Seetharam L, Yamaguchi S, et al: A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/FII-1). Oncogene 1994;9:2683-2690.
14. Mise M, Arii S, Higashitsuji H, et al: Clinical significance of vascular endothelial growth lactor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996;23: 455-464.
15. Suzuki K, Hayashi N, Miyamoto T, et al: Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996;56:3004-3009.
16. Shweiki D, Itin A, Soffer D, et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
17. Ladoux A, Frelin C: Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun 1993;195:1005-1010.
18. 165 in patients with ischaemic limb. Lancet 1996;348:370-374.
19. Panés J, Bordas JM, Piqué JM, et al: Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology 1992;103:1875-1882.
20. Kiel JW, Riedel GI, DiResta GR, et al: Gastric mucosal blood now measured by laser-Doppler velocimetry. Am J Physiol 1985;249:G539-G545.
21. 2 clearance, and microsphere estimates of mucosal blood flow. Am J Physiol 1985;249:G221-G227.
22. Ahn H, Lindhagen J, Nilsson GE, et al: Evaluation of laser Doppler flowmetry in the assessment of intestinal blood flow in cat. Gastroenterology 1985;88:951-957.
23. Christoforidis EC, Hovendal C, Bjerring P, et al: Continuous measurement of gastric blood flow by laser-Doppler flowmetry during endoscopy. Scand J Gastroenterol 1989;24:16-20.
24. Fujita M, Ikemoto M, Kishishita M, et al: Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation 1996;94:610-613.
25. Neuhaus OW, Letzring M: Determination of hexosamines in conjunction with electrophoresis on starch. Anal Chem 1957;29:1230-1233.
26. Hashizume M, Sugimachi K: Classification of gastric lesions associated with portal hypertension. J Gastroenterol Hepatol 1995;10:339-343.
27. Spina G, Archidiacono R: Gastric Endoscopic Features in Portal Hypertension. Milan, Masson, 1994.
28. Lamarque D, Levoir D, Duvoux C, et al: Measurement of gastric intramucosal pH in patients with cirrhosis and portal hypertensive gastropathy. Gastroenterol Clin Biol 1994;18: 969-974.
29. Geraghty JG, Angerson WJ, Carter DC: A study of regional gastric mucosal blood flow in a rat model of hepatic cirrhosis. Am J Physiol 1992;262:G727-G731.
30. Kunisaki C, Sugiyama M: Effect of teprenone on acute gastric mucosal lesions induced by cold-restraint stress. Digestion 1992;53:45-53.
31. Murakami M, Oketani K, Fujisaki H, et al: Antiulcer effect of geranylgeranylacetone, a new acyclic polyisoprcnoid, on experimentally induced gastric and duodenal ulcers in rats. Arzneimittelforschung 1981;31:799-804.
32. Terano A, Shiga J, Hiraishi H, et al: Protective action of tetraprenylacetone against ethanol-induced damage in rat gastric mucosa. Digestion 1986;35:182-188.
33. Itoh Y, Suzuki K, Matsuhara M, et al: Changes in gastric mucosal content of adenosine, xanthine and hypoxanthine induced by restrained water immersion stress: Antiulcer effects of tetraprenylacetone. Digestion 1991;48:25-33.
34. Nishizawa Y, Sakurai H, Oketani K, et al: Effects of taurocholic acid/HCl alone or after pretreatment with geranylgeranylacetone on phospholipid metabolism in rat gastric mucosa. Biochem Pharmacol 1987;36:4111-4117.
35. Bilski J, Murty VLN, Nadziejko C, et al: Protection against alcohol-induced gastric mucosal injury by geranylgeranylacetone: Effect of indomethacin. Digestion 1988;41:22-23.
36. Tarnawski A, Ivey KJ, Stachura J, et al: Protection by prostaglandin against ethanol-induced gastric mucosal damage in man. An endoscopic and histologic assessment (abstract). Gastroenlerology 1981;80:1300.
37. Tarnawski Stachura J, Ivey KJ, et al: Ethanol-induced duodenal lesions in man: Protective effect of prostaglandin. Prostaglandins 1981; 21:147-153.
38. Tarnawski A, Hollander D, Stachura J, et al: Prostaglandin protection of the gastric mucosa against alcohol injury: A dynamic time-related process. Gastroenterology 1985;88:334-352.
39. Lacy ER, Ito S: Microscopic analysis of ethanol damage to rat gastric mucosa after treatment with prostaglandin. Gastroenterology 1982;83: 619-625.
40. Guth PH, Pauken G, Nagata H: Histologic and microcirculatory changes in alcohol-induced gastric lesions in the rat: Effect of prostaglandin cytoprotection. Gastroenterology 1984;87: 1083-1090.
41. Wang JY, Hsieh JS, Huang TJ: Changes in rat gastric mucosal glycoproteins in portal hypertension. Eur Sur Res 1997;29:280-286.
42. Ohta Y, Kobayashi T, Nishida K, et al: Relationship between changes of active oxygen metabolism and blood flow and formation, progression, and recovery of lesions is gastric mucosa of rats with a single treatment of compound 48/80, a mast cell degranulator. Dig Dis Sci 1997;42:1221-1232.
43. Tanoue K, Tarnawski A, Kishihara F, et al: Effect of teprenone on portal hypertensive gastric mucosa. Digestion 1996;57:35-40.
44. Sarfeh IJ, Tarnawski A, Malki A: Portal hypertension and gastric mucosal injury in rats. Gastroenterology 1983;34:987-993.
45. Tarnawski A, Sarfeh IJ, Stachura J, et al: Microvascular abnormalities of the portal hypertensive gastric mucosa. Hepatology 1988;8: 1488-1494.
46. Takahashi M, Kawabe T, Ogura K, et al: Expression of vascular endothelial growth factor at the human gastric ulcer margin and in cultured gastric fibroblast: A new angiogenic factor for gastric ulcer. Biochem Biophys Res Commun 1997;234:493-498.
47. Ostrow JD: Gastric secretion in human hepatic cirrhosis. Gastroenterology 1960;38:303-313.
48. Groszmann RJ: Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences. Hepatology 1994; 20:1359-1361
49. Takahashi M, Ogura K, Maeda S, et al: Promoters of epithelialization induce expression of vascular endothelial growth factor in human gastric epithelial cells in primary culture. FEBS Lett 1997;418:115-118.
50. Nakamura M, Katano M, Fujimoto K, et al: A new prognostic strategy for gastric carcinoma. Ann Surg 1997;226:35-42.
51. Shiraishi S, Nakagawa K, Kinukawa K, et al: Immunohistochemical localization of vascular endothelial growth factor in the human placenta. Placenta 1996;17:111-121.